Molecular proximity orchestrates biological function, and blocking existing proximities is an
established therapeutic strategy. By contrast, strengthening or creating neoproximity with …

Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …

Most life scientists would agree that understanding how cellular processes work requires
structural knowledge about the macromolecules involved. For example, deciphering the …

Proteolysis-targeting chimeras (PROTACs) as an emerging drug discovery modality has
been extensively concerned in recent years. Over 20 years development, accumulated …

Targeted protein degradation has arisen as a powerful therapeutic modality for eliminating
proteins. Thus far, most heterobifunctional proteolysis targeting chimeras (PROTACs) have …

Targeted protein degradation (TPD) has emerged as a promising approach for drug
development, particularly for undruggable targets. TPD technology has also been …

Ribosome-dependent protein biosynthesis is an essential cellular process mediated by
transfer RNAs (tRNAs). Generally, ribosomally synthesized proteins are limited to the 22 …

Numerous therapeutic approaches have been developed to enable interrogation and
modulation of protein isoforms, but often require laborious experimental development or …

Regulated protein degradation in eukaryotes is performed by the 26S proteasome, which
contains a 19-subunit regulatory particle (RP) that binds, processes, and translocates …

Targeted protein degradation (TPD) has been established as a viable alternative to
attenuate the function of a specific protein of interest in both biological and clinical contexts …